You are here

CSL

Q&A: Newly-minted CSL chief executive Paul McKenzie and chief medical officer Bill Mezzanotte

Q&A: Newly-minted CSL chief executive Paul McKenzie and chief medical officer Bill Mezzanotte

Endpoints

Flag link:

CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing

CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing

Drugs.com

clinical trials

Flag link:

First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission

First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission

BioSpace

Flag link:

Big pharma’s new year catalysts

Big pharma’s new year catalysts

EP Vantage

Flag link:

Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small

Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small

Forbes

Flag link:

10 Massachusetts Biopharma Companies Hiring Now

10 Massachusetts Biopharma Companies Hiring Now

BioSpace

Moderna Therapeutics

Intellia Therapeutics

Alloy Therapeutics

Werewolf Therapeutics

Sherlock Biosciences

Flag link:

A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount

A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount

Medical Marketing and Media

Flag link:

uniQure, CSL claim first okay for hemophilia B gene therapy

uniQure, CSL claim first okay for hemophilia B gene therapy

Pharmaphorum

Flag link:

Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies

Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies

Fierce Pharma

Flag link:

CSL makes $4bn+ move in mRNA vaccines with Arcturus deal

CSL makes $4bn+ move in mRNA vaccines with Arcturus deal

Pharmaphorum

Flag link:

CSL takes the wraps off a big new R&D center as it eyes vaccines, cell and gene therapies

CSL takes the wraps off a big new R&D center as it eyes vaccines, cell and gene therapies

Endpoints

Flag link:

CSL reports Phase III data for garadacimab to treat hereditary angioedema

CSL reports Phase III data for garadacimab to treat hereditary angioedema

Clinical Trials Arena

clinical trials

hereditary angiodema

Flag link:

CSL Launches New Unified Global Brand Identity

CSL Launches New Unified Global Brand Identity

BioSpace

Flag link:

After delay, CSL's $11.7B deal for Vifor poised to close next week

After delay, CSL's $11.7B deal for Vifor poised to close next week

Fierce Pharma

Flag link:

CSL's Seqirus caps off $156M expansion of flu manufacturing facility in Raleigh suburb

CSL's Seqirus caps off $156M expansion of flu manufacturing facility in Raleigh suburb

Endpoints

drug manufacturing

Flag link:

Days after buyout news, Vifor outlines plan to offload 'non-core' finished drug manufacturing wing

Days after buyout news, Vifor outlines plan to offload 'non-core' finished drug manufacturing wing

Endpoints

Flag link:

Biopharma’s buyout year ends with a bang

Biopharma’s buyout year ends with a bang

EP Vantage

Arena Pharmaceuticals

Flag link:

As year-end deals start to sizzle, CSL moves a biotech buyout to the front burner with deal expected Tuesday — report

As year-end deals start to sizzle, CSL moves a biotech buyout to the front burner with deal expected Tuesday — report

Endpoints

Flag link:

Takeda, CSL hereditary angioedema meds need steep discounts following real-world evidence review, ICER says

Takeda, CSL hereditary angioedema meds need steep discounts following real-world evidence review, ICER says

Fierce Pharma

hereditary angiodema

Flag link:

Pages